Placebo News and Research

RSS

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that the Instituto de Salud Publica of Chile has approved the Company's protocol for its Phase 2 clinical study of TI-001, intranasal oxytocin, for the treatment of chronic migraine.

9 Apr 2013

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Genzyme, a Sanofi company, announced today Argentina's National Administration of Drugs, Food and Medical Technology has approved once-daily, oral AUBAGIO 14 mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis.

9 Apr 2013

Diclegis gets FDA approval for treatment of nausea and vomiting of pregnancy

The U.S. Food and Drug Administration today approved Diclegis (doxylamine succinate and pyridoxine hydrochloride) to treat pregnant women experiencing nausea and vomiting.

9 Apr 2013

FDA grants priority review for Bayer HealthCare's riociguat for treatment of CTEPH

Bayer HealthCare announced today that the New Drug Application for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration for the treatment of inoperable chronic thromboembolic pulmonary hypertension or with persistent or recurrent CTEPH after pulmonary endarterectomy and pulmonary arterial hypertension.

8 Apr 2013

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

KYTHERA Biopharmaceuticals, Inc. today announced positive interim results from a Phase IIIb, multicenter, open-label study (ATX-101-11-26) of ATX-101 during the "Innovations and Renewals" session of the 11th Anti-Aging Medicine World Congress, April 4-6, Monte Carlo, Monaco.

8 Apr 2013

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase inhibitor in development for rheumatoid arthritis.

6 Apr 2013

Arena Pharmaceuticals kicks off APD334 Phase 1 clinical trial for treatment of autoimmune diseases

Arena Pharmaceuticals, Inc. announced today the initiation of dosing in a Phase 1 clinical trial of APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases.

6 Apr 2013

Clinical trial signals new era in treatment of neurodegererative disorders

The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis - blocking production of a mutant protein that causes an inherited form of the progressive neurodegererative disease - may be a first step towards a new era in the treatment of such disorders.

4 Apr 2013

Reformulated version of anti-HIV gel safe for HIV-negative men and women

A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally, according to a Phase I clinical trial published today in PLOS ONE.

4 Apr 2013

Researchers confirm effectiveness of spray that improves dry mouth

Researchers from the universities of Granada and Murcia have confirmed the effectiveness of a spray containing 1% malic acid, which greatly improves xerostomy, or dry mouth, caused by anti-depressant drugs.

4 Apr 2013

Study: V710 vaccine does not reduce postoperative Staphylococcus aureus infections

Use of a vaccine to prevent Staphylococcus aureus infections among patients undergoing cardiothoracic surgery did not reduce the rate of serious postoperative S aureus infections compared with placebo and was associated with increased mortality among patients who developed S aureus infections, according to a study in the April 3 issue of JAMA.

3 Apr 2013

Duloxetine drug alleviates pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA.

3 Apr 2013

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Ulcerative colitis (UC) and Crohn’s disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.

From Takeda 3 Apr 2013

Isis Pharmaceuticals starts ISIS-APOARx Phase 1 clinical study for treatment of atherosclerosis

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis.

3 Apr 2013

Biogen acquires TYSABRI stake from Elan

Biogen Idec today announced it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI.

3 Apr 2013

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has dosed the first patient in its second Phase 2 clinical study with LiRIS, its novel product candidate, in patients with Interstitial Cystitis.

3 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

Placebo News and Research

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Diclegis gets FDA approval for treatment of nausea and vomiting of pregnancy

FDA grants priority review for Bayer HealthCare's riociguat for treatment of CTEPH

KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101

AstraZeneca reports fostamatinib Phase 3 study results for treatment of rheumatoid arthritis

Arena Pharmaceuticals kicks off APD334 Phase 1 clinical trial for treatment of autoimmune diseases

Clinical trial signals new era in treatment of neurodegererative disorders

Reformulated version of anti-HIV gel safe for HIV-negative men and women

Researchers confirm effectiveness of spray that improves dry mouth

Study: V710 vaccine does not reduce postoperative Staphylococcus aureus infections

Duloxetine drug alleviates pain from chemotherapy

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Isis Pharmaceuticals starts ISIS-APOARx Phase 1 clinical study for treatment of atherosclerosis

Biogen acquires TYSABRI stake from Elan

First patient dosed in second Phase 2 study with LiRIS for treatment of Interstitial Cystitis

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

Ampio Pharmaceuticals receives FDA IND approval to start clinical trial of Ampion

New evidence shows older adults with dementia can be taken off antipsychotic medications

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News